Aciclovir, written as acyclovir in most US labeling and procurement systems, is an antiviral active pharmaceutical ingredient (API) that generic manufacturers formulate into tablets, creams, ointments and injectables. The molecule targets herpes simplex virus (HSV-1 and HSV-2) and varicella-zoster virus, which places it in finished products associated with cold sores, genital herpes, shingles and chickenpox. Because the compound is long off patent, US demand is driven by generic producers and contract formulators who buy bulk API on tight margins. For these buyers, small shifts in input costs, energy and trade policy can reshape annual budgets. This article reviews what ChemAnalyst reported for the second quarter of 2026 (the quarter ending June 2026), how the US compares with China and Germany, and which supply chain and tariff questions procurement teams should keep on their radar. It is a market discussion only and does not offer medical advice.
US Aciclovir Price Trend
According to ChemAnalyst, aciclovir prices in the United States moved higher in Q2 2026 compared with the previous quarter. The firm attributes the increase mainly to producer inflation and rising production costs rather than to a sudden surge in end demand. No public US dollar figure for Q2 2026 has been released, so buyers who need a benchmark for contract talks should consult the latest aciclovir price assessment from ChemAnalyst, which tracks quarterly movements by region.
For context on the wider cost picture, ChemAnalyst's own regional data point offers a reference: the firm assessed aciclovir in China at USD 54,840 per metric ton in Q4 2025. ChemAnalyst did not attach an Incoterm to that figure, so it should be treated as an indicative level rather than a landed US cost. Freight, duties, documentation and qualification costs would all sit on top of any Asian assessment before material reaches a US plant.
What Drove Acyclovir Prices in Q2 2026
ChemAnalyst links the US quarterly rise to several macro and cost signals:
- Producer inflation: ChemAnalyst cites the US Producer Price Index rising 6.5% year over year in May 2026, a sign that upstream manufacturing costs were climbing across industries.
- Consumer spending: US retail sales were up 6.9% year over year in May 2026, according to the figures ChemAnalyst references, indicating that broader demand conditions remained firm.
- Logistics: Freight rates were higher earlier in 2026, which ChemAnalyst notes added to delivered costs.
- Energy offset: Natural gas inventories stood above the five-year average at the end of June 2026, which ChemAnalyst says limited energy-related cost pressure during the quarter.
Taken together, these factors suggest that the Q2 increase was cost-led. For buyers, that matters: cost-led increases tend to be stickier than demand spikes, because suppliers pass through inputs they cannot easily cut.
US vs Asia and Europe
The US was not alone in seeing higher prices. ChemAnalyst reports quarter-over-quarter gains in both China and Germany, although the drivers differed.
China. Prices rose on production costs. ChemAnalyst points to China's PPI increasing 4.1% year over year in June 2026, planned electricity price increases in June, and disruptions to crude oil and coal imports during April and May. Domestic consumption did not provide the push: China's retail sales fell 0.6% year over year in May 2026, according to ChemAnalyst. In other words, Chinese producers faced higher input and utility bills even as local spending softened.
Germany. ChemAnalyst attributes the German increase to production costs and supply disruptions. Producer prices rose 2.2% in May 2026, energy inflation was evident in April, and chemical feedstock inventories were tighter. ChemAnalyst expects European prices to stay elevated in the near term.
For US procurement teams that dual-source from Asia and Europe, the common thread is that every major region reported cost pressure in Q2 2026. That narrows the room to play one origin against another on price alone. A side-by-side view is available through ChemAnalyst's regional acyclovir pricing data.
Supply Chain and Trade Risk for US Buyers
Trade policy is the largest open question for 2026 and 2027 planning. The US has introduced Section 232 tariffs on pharmaceuticals, with a 100% standard rate on patented pharmaceuticals and their APIs. The measure takes effect on 31 July 2026 for companies listed in Annex III and on 29 September 2026 for all others.
Generic products are treated differently for now. A trade compliance summary from GHY, updated 28 September 2026, states that "Generic pharmaceuticals, biosimilars, and their ingredients are not subject to Section 232 tariffs at this time." The same summary notes that the Commerce Department must reassess that position within one year. Since aciclovir is an off-patent generic API, it currently sits outside the tariff, but the reassessment is a clear watch item.
Practical steps procurement teams can consider:
- Map which acyclovir supply contracts would be exposed if generic APIs were brought into scope after the Commerce review.
- Review contract clauses on tariff pass-through, price adjustment triggers and force majeure.
- Track energy and feedstock signals in China and Germany, since ChemAnalyst ties recent price moves in both regions to those inputs.
- Build freight variability into landed-cost models, given the higher rates seen earlier in 2026.
Teams preparing a tender or renewal can request an aciclovir price quote to compare current offers against ChemAnalyst's regional assessments.
Outlook
ChemAnalyst's Q2 2026 reading points to a cost-driven market in all three regions it covered. In Europe, the firm expects prices to remain elevated. In the US, elevated producer inflation was partly balanced by comfortable natural gas inventories, which kept energy from adding further pressure. In China, power tariffs and import disruptions raised costs even as consumer spending dipped.
The policy calendar adds a second layer. Generic APIs, including aciclovir, are outside Section 232 for now, but the mandatory one-year reassessment means buyers should not assume that exemption is permanent. Firms that review sourcing exposure early will have more options if the scope changes.
FAQ
Is aciclovir the same as acyclovir?
Yes. Aciclovir is the international nonproprietary spelling and acyclovir is the spelling commonly used in the US. Both refer to the same antiviral API.
Why did US aciclovir prices rise in Q2 2026?
ChemAnalyst attributes the quarter-over-quarter increase mainly to producer inflation and higher production costs, citing US PPI up 6.5% year over year in May 2026 and higher freight rates earlier in the year.
Are acyclovir APIs subject to the Section 232 pharmaceutical tariff?
Not at this time. GHY's summary, updated 28 September 2026, says generic pharmaceuticals and their ingredients are currently excluded, but Commerce must reassess within one year.
Where can I find a current US price for aciclovir?
No public Q2 2026 US figure has been published. ChemAnalyst's pricing page and quote request form are the most direct routes to current numbers.
Comments